What Can Cause High Blood Pressure and When Is ABPM Useful?

Direct Answer

High blood pressure usually develops from a long-term interaction among genetics, aging, kidney sodium handling, vascular stiffness, body weight, diet, physical activity, alcohol, sleep, and social or environmental exposures. This is called primary hypertension and it does not have one single identifiable cause. Secondary hypertension has a specific cause, such as kidney disease, primary aldosteronism, obstructive sleep apnea, thyroid disease, pregnancy, or a medicine or stimulant. One high office reading may also reflect pain, stress, caffeine, incorrect technique, or a white-coat effect rather than sustained hypertension. Confirm the pattern with standardized repeat measurements and, when indicated, validated out-of-office monitoring. WHO hypertension overview [1]

Key Takeaways

• Most hypertension is primary and multifactorial; a smaller but clinically important group has an identifiable secondary cause.
• Common modifiable contributors include excess sodium, excess body weight, physical inactivity, heavy alcohol use, inadequate sleep, and certain medicines or stimulants.
• Kidney disease, primary aldosteronism, renovascular disease, obstructive sleep apnea, thyroid disorders, pheochromocytoma, Cushing syndrome, and aortic coarctation are important secondary causes.
• ABPM helps confirm whether blood pressure is persistently high and reveals white-coat, masked, daytime, and nighttime patterns; it does not diagnose the underlying cause by itself.
• Procurement teams should require model-specific regulatory authorization, validation evidence, intended-use labeling, cuff-range coverage, software documentation, and service controls—not broad brand-level claims.

A High Reading Is Not Automatically Chronic Hypertension

Blood pressure changes from minute to minute. Pain, anxiety, recent exercise, nicotine, caffeine, a full bladder, talking during measurement, an unsupported arm, or an incorrectly sized cuff can temporarily raise a reading. White-coat hypertension produces elevated clinic readings with lower out-of-office values; masked hypertension does the reverse. NICE recommends ABPM to confirm diagnosis when clinic blood pressure is 140/90 to 180/120 mmHg, using the average of at least 14 waking-hour measurements. NICE NG136 [4]

A single number therefore answers only one question: what the pressure was at that moment under those conditions. Diagnosis requires repeated, standardized measurements interpreted with medical history, examination, cardiovascular risk, and evidence of organ damage.

Urgent safety note. A blood pressure around 180/120 mmHg or higher with chest pain, shortness of breath, confusion, weakness, vision change, severe headache, or other acute symptoms requires immediate medical assessment. Do not delay care to complete ambulatory monitoring. WHO warning symptoms [1]

How Blood Pressure Becomes Persistently Elevated

Arterial pressure reflects cardiac output and resistance within the circulation. The kidneys regulate sodium and fluid balance; the sympathetic nervous system changes heart rate and vascular tone; the renin-angiotensin-aldosterone system (RAAS) affects vasoconstriction and aldosterone-mediated sodium retention; and blood-vessel structure determines stiffness and resistance. In primary hypertension, multiple small disturbances accumulate over time. Genetic susceptibility can interact with aging, high sodium intake, obesity, inactivity, alcohol, poor sleep, and chronic environmental or psychosocial stressors.

The 2024 European Society of Cardiology guideline describes hypertension as an interaction among environmental and behavioral factors, genes, hormonal networks, renal, cardiovascular, and central nervous systems, plus vascular and immune mechanisms. It also emphasizes that most patients have primary hypertension, while secondary hypertension has an identifiable cause. 2024 ESC guideline [3]

Primary Drivers and Secondary Causes

Cause or Driver	Mechanism / Examples	Clues	Clinical Next Step
Long-term primary drivers	Aging, family history, excess sodium, overweight/obesity, inactivity, excess alcohol, poor sleep, unhealthy diet, and environmental or social stressors	Usually gradual; often clusters with diabetes, dyslipidemia, or kidney risk	Confirm persistent BP; assess total cardiovascular risk; address lifestyle and treatment
Kidney disease	Impaired sodium/fluid handling and RAAS activation	Abnormal creatinine/eGFR, urine blood or protein, edema, kidney history	Creatinine/eGFR, electrolytes, urinalysis, urine albumin-to-creatinine ratio; imaging when indicated
Primary aldosteronism	Excess aldosterone increases sodium retention and potassium loss	Resistant or severe hypertension; hypokalemia may occur but can be absent	Aldosterone-to-renin ratio under a clinician-directed protocol
Renovascular hypertension	Reduced renal perfusion activates RAAS	Abrupt onset/worsening, abdominal bruit, flash pulmonary edema, renal-function change	Renal vascular imaging when clinical suspicion is sufficient
Obstructive sleep apnea	Intermittent hypoxia and sympathetic activation	Snoring, witnessed apneas, daytime sleepiness, obesity, resistant or nondipping BP	Sleep evaluation and polysomnography or validated sleep testing
Endocrine/vascular causes	Thyroid disease, Cushing syndrome, pheochromocytoma/paraganglioma, hyperparathyroidism, or aortic coarctation	Cause-specific symptoms, episodic BP, endocrine findings, arm-leg gradient	Targeted biochemical testing and imaging; specialist referral
Pregnancy-related hypertension	Pregnancy-specific vascular and placental mechanisms	New hypertension during pregnancy or postpartum; headache, visual or upper-abdominal symptoms may be concerning	Urgent obstetric assessment; use pregnancy-specific guidance
Medicines and substances	Sodium retention, sympathetic stimulation, hormonal effects, or vascular/endothelial effects	Temporal relationship to NSAIDs, decongestants, stimulants, corticosteroids, contraceptives, immunosuppressants, certain antidepressants, licorice, cocaine, or methamphetamine	Reconcile all prescriptions, over-the-counter products, supplements, nicotine, alcohol, and recreational substances

Sources: ESC 2024 guideline [3], NHLBI [5], and WHO [1]. The table supports screening decisions; it is not a diagnostic algorithm for self-use.

When to Look More Closely for a Secondary Cause

Secondary hypertension becomes more likely when the pattern does not fit gradual primary hypertension. The trigger is not any one clue but the combination of severity, timing, resistance to treatment, laboratory findings, and the patient’s age and history.

• Abrupt onset or a sudden worsening of previously stable blood pressure.
• Severe hypertension, a hypertensive emergency, or organ damage disproportionate to the known duration of hypertension.
• Hypertension that remains uncontrolled despite an appropriate multidrug regimen and confirmed adherence.
• Young age at onset, especially when no strong family or lifestyle explanation is present.
• Hypokalemia, abnormal kidney function or urinalysis, episodic headache/palpitations/sweating, or an arm-leg blood-pressure difference.
• Loud snoring, witnessed apneas, daytime sleepiness, or a nondipping nighttime pattern.
• A medication, supplement, substance, or pregnancy timeline that coincides with the elevation.

The ESC guideline recommends that primary care participate in screening for common secondary causes, especially sleep apnea and primary aldosteronism, and lists cause-specific screening tests. ESC secondary hypertension section [3]

What ABPM Adds—and What It Cannot Do

A 24-hour ambulatory blood pressure monitor records repeated upper-arm measurements during usual activities and sleep. It can distinguish sustained hypertension from a white-coat effect, uncover masked hypertension, quantify daytime and nighttime averages, and show whether blood pressure falls during sleep. These patterns may strengthen the case for further evaluation—for example, a nondipping pattern in a patient with sleep-apnea symptoms—but they do not identify the disease causing hypertension.

Method	Best Contribution	Main Limitation	Typical Use
Standardized office BP	Immediate clinical assessment; repeatable under supervision	White-coat effect, limited sampling, technique sensitivity	Initial screening, urgent triage, routine follow-up
ABPM	Day/night profile; white-coat and masked hypertension; many readings in usual life	Wear burden, failed readings, sleep disturbance, device/patient restrictions; cannot determine etiology	Diagnostic confirmation, discordant readings, resistant hypertension, nocturnal-pattern questions
HBPM	Repeated measurements over several days; familiar setting	Depends on validated device, patient technique, schedule, and reliable recording	Alternative when ABPM is unsuitable; ongoing self-monitoring with training

For U.K. practice, NICE keeps ABPM as the preferred confirmation method and specifies at least two measurements per hour during waking hours and at least 14 valid waking readings for the diagnostic average. Thresholds and protocols differ across guidelines and patient groups, so procurement requirements should reference the institution’s adopted clinical pathway rather than a generic web threshold. NICE recommendations [4]

A Practical Eight-Step Hospital Workflow

1. Standardize the initial measurement: confirm rest, posture, arm support, cuff size, and repeated readings; check both arms when first evaluating hypertension.
2. Triage urgency: if very high pressure is accompanied by possible acute organ injury symptoms, arrange immediate clinical assessment rather than ABPM.
3. Confirm persistence: use repeat office measurements and validated ABPM or HBPM according to the applicable guideline and local protocol.
4. Review context: reconcile prescriptions, over-the-counter medicines, supplements, alcohol, nicotine, stimulants, sleep, pain, and recent illness.
5. Assess total risk and organ effects: document cardiovascular history, diabetes, kidney status, lipids, smoking, examination findings, and relevant laboratory tests.
6. Screen selectively for secondary causes: choose tests from the patient’s red flags rather than ordering every possible endocrine or imaging study.
7. Interpret ABPM clinically: verify sufficient valid readings, diary timing, sleep/wake periods, cuff fit, artifacts, and whether results match the clinical question.
8. Close the loop: record the diagnosis or unresolved question, initiate or adjust management under a licensed clinician, and schedule follow-up or specialist referral.

Procurement Evidence: United States vs. European Union

Regulatory documents are market- and model-specific. A manufacturer’s quality certificate, facility registration, or a clearance for another model cannot substitute for the authorization and labeling of the device being purchased.

Evidence Area	United States	European Union
Market authorization	Verify the exact model in FDA’s 510(k), De Novo, or PMA database as applicable. WBP-02A is 510(k)-cleared under K251581; call it ‘FDA cleared,’ not ‘FDA approved.’	Verify MDR conformity for the exact model: risk classification, applicable conformity-assessment route, CE mark, EU Declaration of Conformity, and Notified Body certificate/number when required.
Registration / database	Establishment registration and device listing are separate from premarket clearance and do not denote approval. Check UDI/GUDID and current listing as applicable.	Verify Actor/SRN, Basic UDI-DI/UDI-DI, device registration, Notified Body certificate, and economic-operator data in EUDAMED where applicable. The first four EUDAMED modules became mandatory on May 28, 2026.
Quality system	FDA’s QMSR became effective February 2, 2026 and incorporates ISO 13485:2016 by reference, with additional U.S. requirements.	Request a current ISO 13485 certificate with scope, issuing body, sites, and validity; also review MDR-specific post-market, vigilance, and economic-operator obligations.
Performance evidence	510(k) summary, intended-use labeling, test reports referenced in the submission, cybersecurity/software documentation, and model-specific validation.	Clinical evaluation, risk management, technical documentation, performance/accuracy validation, IFU/labels in required languages, and post-market evidence.
Tender controls	Match 510(k) model name, accessories, cuff ranges, software version, Rx status, intended population, exclusions, UDI, service, and complaint/recall processes.	Match Basic UDI-DI and model, certificate scope, Notified Body, authorized representative/importer, local language, UDI, software, vigilance, service, and transitional status if relevant.

Primary sources: FDA K251581 [6]; FDA registration reminder; FDA QMSR; EU MDR Articles 19-20; and European Commission EUDAMED overview.

Hingmed Model Fit: Use Verified, Model-Specific Language

The FDA cleared WBP-02A on February 13, 2026 under K251581 as a Class II noninvasive blood-pressure measurement system. The FDA summary describes an upper-arm, oscillometric, tubeless ambulatory monitor with USB transfer to offline PC software and storage for up to 300 records. It is prescription-only, intended for people aged 12 years and older, and is not intended for diabetic patients, pregnant women, or patients with arrhythmia; additional listed restrictions also apply. The PC software supports professional review and does not replace healthcare-professional tasks. FDA 510(k) summary [6]

The FDA summary reports validation to ISO 81060-2:2018+A1:2020, including a 95-subject general study and a 36-subject ambulatory supplementary study. STRIDE BP also lists WBP-02A as an available upper-arm oscillometric device for 24-hour ambulatory use with a published validation study. STRIDE BP listing [9]

Model	Potential Workflow Fit	Evidence Position
WBP-02A	Tubeless upper-arm ABPM; USB to offline PC software	U.S. 510(k) K251581 is verified. Validate tender configuration, IFU, cuff range, software version, accessories, and target-market documents.
WBP-02 BT	Manufacturer describes tubeless design with Bluetooth data transfer	Treat connectivity, validation, regulatory status, population, and software/security claims as manufacturer claims until model-specific evidence is supplied.
WBP-02 Wi-Fi	Manufacturer describes Wi-Fi upload and network workflow	Require architecture, encryption, authentication, data-flow, cybersecurity, interoperability, privacy, downtime, and market-authorization documentation before tender acceptance.

Manufacturer pages: WBP-02A, WBP-02 BT, and WBP-02 Wi-Fi. Manufacturer pages are not substitutes for regulatory or validation files.

Hospital ABPM Procurement Checklist

• Define the clinical pathway: confirmation, resistant hypertension, nocturnal assessment, research, or networked service.
• Verify the exact model’s authorization in every target market; do not accept brand-level certificates.
• Match the intended population, prescription status, contraindications, and exclusions to the hospital’s patient mix.
• Obtain the current IFU, labeling, UDI, accessories list, cuff sizes, and supported wear/measurement protocol.
• Review the full model-specific validation report, protocol version, sample, cuff sizes, investigators, and special populations.
• Confirm the device is independently listed by an appropriate validation organization where relevant, without overstating listing as endorsement.
• Evaluate valid-reading rate, motion handling, repeat-measurement logic, patient diary support, and failure alerts.
• Test device setup, fitting, cleaning, charging/battery, download, report review, and redeployment in the actual clinic workflow.
• Verify software version, operating-system support, data export, audit trail, user roles, time synchronization, backups, and retention.
• For Bluetooth/Wi-Fi workflows, review encryption, authentication, network segmentation, vulnerability handling, update policy, and downtime mode.
• Confirm integration scope: interfaces, data dictionary, patient matching, EMR/HIS responsibilities, validation, and change control.
• Assess cleaning/disinfection compatibility, cuff replacement, consumables, calibration/maintenance, service response, spares, and training.
• Request quality-system scope, complaint handling, vigilance/recall process, post-market surveillance, and local economic-operator details.
• Run a controlled pilot with acceptance criteria for comfort, valid readings, nighttime completion, report usability, and support burden.
• Document which evidence was verified, which was manufacturer-provided, and which remains a condition of award or deployment.

Common Errors and Risks

• Treating one high reading as proof of chronic hypertension.
• Using an incorrect cuff size or nonstandard patient position, then escalating care from an artifact.
• Assuming ABPM identifies a kidney, endocrine, sleep, or medication cause; it characterizes pressure patterns only.
• Applying a single diagnostic threshold across countries, guidelines, ages, pregnancy, and special populations.
• Calling FDA registration, listing, or 510(k) clearance ‘FDA approval.’
• Extending evidence from one model, software version, cuff, population, or market to an entire product family.
• Buying a connected device without validating cybersecurity, data ownership, interfaces, downtime, updates, and local privacy obligations.

Limitations and Considerations

Hypertension definitions, treatment thresholds, and out-of-office protocols vary among guidelines and patient groups. ABPM may be uncomfortable, can disturb sleep, and can generate failed or motion-affected readings. A technically valid recording still requires clinical interpretation. Special populations need evidence and labeling that actually include them. For WBP-02A in the United States, the FDA summary’s excluded populations and other restrictions must be respected; content or tenders must not broaden the cleared intended use.

The public Hingmed pages contain statements such as ‘FDA Approved,’ ‘FDA certified,’ ‘CE certified,’ ‘ESH/BHS recommended,’ and broad accuracy or AI language. This article uses only narrower wording supported by the FDA record, STRIDE BP, or clearly labeled manufacturer information. EU MDR status, CE documentation, model-level evidence for WBP-02 BT/Wi-Fi, and software/privacy claims require document review before publication or procurement.

FAQ

1. How do ACE inhibitors and ARBs work differently?

Both reduce signaling through the RAAS. ACE inhibitors reduce conversion of angiotensin I to angiotensin II and also reduce bradykinin breakdown. ARBs selectively block angiotensin II at the AT1 receptor and do not directly inhibit bradykinin breakdown. Both can lower vascular resistance and aldosterone-related sodium retention, but their adverse-effect profiles differ.

2. Which conditions favor an ACE inhibitor or an ARB?

The choice depends on the condition, guideline, kidney function, pregnancy potential, prior reactions, and other medicines. NICE includes an ACE inhibitor or ARB as step-1 therapy for selected adults with hypertension and notes condition-specific guidance for diabetes, chronic kidney disease, heart failure, and secondary prevention after myocardial infarction. An ARB is commonly used when ACE-inhibitor cough is not tolerated. Individual selection requires a prescriber.

3. Why can an ACE inhibitor cause a dry cough while an ARB usually does not?

ACE also degrades bradykinin and substance P. ACE inhibition can allow these mediators to accumulate in the respiratory tract and sensitize the cough reflex. ARBs block the AT1 receptor without inhibiting ACE, so they do not usually produce the same bradykinin-mediated cough pattern.

4. Who should not use an ACE inhibitor or ARB?

Important restrictions include pregnancy, prior serious class-specific hypersensitivity or angioedema considerations, and clinical situations where renal perfusion or potassium risk makes therapy unsafe. Bilateral renal-artery stenosis, acute kidney injury, volume depletion, hyperkalemia, and interacting medicines require careful evaluation. Exact contraindications differ by drug and label; clinicians must check the product information and patient context.

5. Can an ACE inhibitor and ARB be used together?

Not routinely for hypertension. NICE says not to combine them for hypertension, and the EMA restricts dual RAAS blockade because the combination increases risks such as hyperkalemia, kidney injury, and hypotension. Rare specialist-directed exceptions in other conditions require close monitoring.

6. What should be monitored during ACE inhibitor or ARB therapy?

Monitor blood pressure, renal function (creatinine/eGFR), and serum potassium; sodium and clinical volume status may also matter. Baseline testing and repeat testing after initiation or dose increases are standard, with timing adjusted to kidney function, potassium, age, comorbidities, and interacting medicines. KDIGO advises checking BP, creatinine, and potassium within 2-4 weeks after starting or increasing a RAAS inhibitor in CKD.

7. Can stress or caffeine cause high blood pressure?

They can raise blood pressure temporarily, and chronic stress can influence behaviors and physiology that increase long-term risk. A temporary trigger does not exclude persistent hypertension. Standardized repeat measurements and out-of-office monitoring help separate a short-lived rise from a sustained pattern.

8. Can ABPM tell which disease caused hypertension?

No. ABPM confirms patterns—such as sustained, white-coat, masked, or nighttime hypertension—but it does not identify an endocrine, kidney, vascular, sleep, medication, or pregnancy-related cause. History, examination, laboratory testing, and targeted imaging establish the cause.

Medication references: NICE NG136 [4]; EMA dual RAAS restriction [8]; KDIGO 2024 CKD guideline [7]; and NCBI ACEI/ARB evidence review.

Next Step for Hospital Buyers

Build the tender around the clinical question and the exact model—not around general claims. For WBP-02A, request the model-specific validation report, current technical specification, U.S. 510(k) documentation, applicable EU MDR/CE package, IFU, software/cybersecurity file set, cuff/accessory list, service plan, and a controlled workflow demonstration.

Request the model-specific validation report, technical specification, and procurement package: Contact Hingmed

References

1. World Health Organization. Hypertension. 2025. WHO. https://www.who.int/news-room/fact-sheets/detail/hypertension. Accessed August 20, 2026.
2. American Heart Association. Top Things to Know: 2025 High Blood Pressure Guideline. 2025. Professional Heart Daily. https://professional.heart.org/en/science-news/2025-high-blood-pressure-guideline/top-things-to-know. Accessed August 20, 2026.
3. McEvoy JW, et al. 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension. 2024. European Heart Journal. https://academic.oup.com/eurheartj/article/45/38/3912/7741010. Accessed August 20, 2026.
4. National Institute for Health and Care Excellence. Hypertension in Adults: Diagnosis and Management (NG136). 2019; updated February 26, 2026. NICE. https://www.nice.org.uk/guidance/ng136. Accessed August 20, 2026.
5. National Heart, Lung, and Blood Institute. High Blood Pressure: Causes and Risk Factors. 2024. NIH. https://www.nhlbi.nih.gov/health/high-blood-pressure/causes. Accessed August 20, 2026.
6. U.S. Food and Drug Administration. 510(k) Premarket Notification K251581: Wearable Ambulatory Blood Pressure Monitor (WBP-02A). Decision February 13, 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251581.pdf. Accessed August 20, 2026.
7. Kidney Disease: Improving Global Outcomes. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2024. Kidney International. https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf. Accessed August 20, 2026.
8. European Medicines Agency. Combined Use of Medicines Affecting the Renin-Angiotensin System to Be Restricted. 2014. EMA. https://www.ema.europa.eu/en/news/combined-use-medicines-affecting-renin-angiotensin-system-ras-be-restricted-chmp-endorses-prac-recommendation. Accessed August 20, 2026.
9. STRIDE BP. Hingmed WBP-02A Device Listing. STRIDE BP. https://www.stridebp.org/device/hingmed-wbp-02a/. Accessed August 20, 2026.
10. Fania C, Meggiolaro E, De Franceschi D, Palatini P. Accuracy of the WBP-02A Device for Ambulatory Blood Pressure Measurement According to the Universal Protocol. 2025. International Journal of Cardiology Research & Reviews. https://cmeonlinelibrary.com/pdfs/accuracy-of-the-wbp02a-device-for-ambulatory-blood-pressure-measurement-according-to-the-universal-protocol-28.pdf. Accessed August 20, 2026.